Duchenne Muscular Dystrophy Flashcards

1
Q

What is DMD the result of?

A

mutations in dystrophin gene (protein)

results in progressive muscle degeneration

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What kind of genetic mutation is DMD?

A

X linked recessive (though can occur secondary to a spontaneous mutation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

how does the weakness progress?

A

Proximal to distal

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Who are the carriers?

A

Women are the carriers but usually exhibit no symptoms

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

When is there loss of ambulation without Tx?

A

Typically between 7-12 y.o.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Can the natural history be changed? if yes how?

A

Yes, by targeting interventions to known manifestations and complications. (steroids, etc)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

When is DMD typically diagnosed?

A

5 years of age

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What are the initial sx?

A

Abnormal muscle function.
Delayed walking, frequent falls, difficulty running/climbing stiars, gowers sign, gait abnormalities, pseudo hypertrophy of calves, increased CK

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

DMD effects on MSK system

A

Mechanical damage; increased permeability of muscle membrane, reduced blood flow to skeletal muscle during exercise, decreased bone mineral density.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What does mechanical damage lead to?

A

Decreased tissue compliance/elasticity, loss of regenerative capability, fibrosis, increased collagen density, reduced maximal force production and fatigue resistance.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What is mechanical damage?

A

Dystrophin provides stability to muscles during function, without it muscle is more vulnerable to damage. Dystrophin increases tensile strength. Chronic damage/muscle breakdown (increased serum CK)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Stages of DMD

A
Pre-Symptomatic
Early ambulatory
Late ambulatory
Early non-ambulatory
Late non-ambulatory
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Pre-symptomatic DMD

A

Possible developmental delay (freq falls, dealyed motor milestones etc)
Gait abnormalities not typically evident
Generally not Dx during this phase

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Early Ambulatory DMD

A

GOWERS SIGN!
Waddling gait/duchenne jog
Can climb stairs with compensatory pattern
May see some imp in gross motor but plateau eventually
No specialized mobility equipment typically needed prior to school age

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Late ambulatory DMD

A

Increasingly labored gait
Loss of ability to climb stairs and rise from floor ind
Difficulty with antigravity extension
inc LE contractures with dc amb
decreased mot to participate
access to mobility device may help keep up with peers

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Early non-ambulatory

A

Typically able to sit ind, bed mobility may be difficult
Often need adaptive equipment and some assistance with bathing, toileting, and transfers
might be able to self propel wheelchair might not
increased risk for scoliosis

17
Q

Late non-ambulatory

A

UE function, postural maintenance and bed mobility increasingly limited.
Increased need for caregiver assistance for all ADLs/repositioning
Increasing need for assistive technology
Increasing use of respiratory support
Increasing reports of chronic pain

18
Q

Pharmocological interventions

A

Glucocorticoids

Deflazacort

19
Q

Glucocorticoids

A

currently the only med that slows decline in muscle strength and function in DMD. Helps preserve ambulation, minimize resp, cardiac and orthopedic complications.

20
Q

Deflazacort or Prednisone

A

Work similarly. Deflazacort not currently approved by FDA. lower risk of weight gain.

21
Q

Initiatio of Glucocorticoid therapy

A

not rec for child who is still gaining motor skills, rec during plateau phase (no progress with motor skills, prior to decline (4-8 y.o.)

22
Q

Use of glucocorticoids after loss of ambulation

A

Medication continued to help preserve upper limb strength, reduce progression of scoliosis, and delay decline in respiratory and cardiac function

23
Q

Glucocorticoids side effects

A
Cushingoid features
Weight gain, obesity
Growth suppression 
Bone demineralization
Increased fracture risk 
Adverse behavioral changes
Delayed puberty
Increased susceptibility to infection
Hypertension
Glucose intolerance
Cataracts
24
Q

areas of psychosocial risk

A

Social functioning due to biological or physical limitations
Learning disorders and/or cognitive delays
Speech and language deficits
Neurobehavioral and/or neurodevelopmental disorders
Oppositional/argumentative behavior
Anxiety or depression (patient and family)

25
Q

Respiratory intervention

A
Volume recruitment
Manual/Mechanical assisted cough
Nocturnal ventilation (BiPAP)
Daytime ventilation
Tracheostomy
26
Q

Cardiac function

A

cardiomyopathy and arrythmias common, baseline of cardiac function at Dx important. (at least before 6 y.o.) - cardiac meds: ace inhibitors, beta blockers, diuretics.
GLucocorticoids = hypertension

27
Q

If theres back pain whats the red flag thought?

A

Vertebral Fracture

28
Q

Role as a PT

A

systematic documentation of disease progression, prolong independence, slow progression, improve QOL.

29
Q

PT assessment

A

Hx (# falls), strength, PROM (every 3-6 mo), posture/symmetry, Gait, Timed testing, motor function scales

30
Q

What should you check PROM of?

A
Heelcords
Hamstrings
Hip flexors
Iliotibial bands
Knee extension 
Long finger flexors
Pronators
Elbow extension
Shoulder abduction/flexion
31
Q

Periodic therapy

A

Monthly or at regularly scheduled intervals
Usually every 3-6 months for this population
Monitor ROM, assess function, provide treatment and update home program
We follow Clinical Pathways/Algorithms to guide frequency and intervention

32
Q

Consultative Therapy

A

As necessary

Due to change in status or new technology/equipment availability

33
Q

What should be a primary focus of therapy?

A

Active, passive, positional (prolonged elongation) stretches –> Heelcords (primarily gastroc), hamstrings, hip flexors, IT bands, pronators, long finger flexors
Knee extension, elbow extension, shoulder abduction/flexion
Long sitting with AFOs for hamstrings and heelcords
Wedge standing, runners stretch for heelcords
Frequency: daily (at home, school, and clinic)

34
Q

What kind of orthotics are good for this?

A

Night time resting AFOs set at comfortable end range dorsiflexion. - goal is not to stretch
AFOs during ambulation are not indicated

35
Q

Early Ambulatory AD

A

Lightweight manual mobility device to be pushed for long distances
Adapted stroller
Ultra-lightweight manual w/c

36
Q

Late Ambulatory AD

A

power assist wheelchair

37
Q

Exercise recommendations

A

Some recommend sub-maximum aerobic exercise while others emphasize avoidance of overexertion and overwork weakness
High-resistance strength training and eccentric exercise are inappropriate across the lifespan
Muscle pain or myoglobinuria in 24 hour period after activity sign of overexertion and contraction-induced injury
Aquatic therapy and swimming may be appropriate
Education regarding energy conservation is appropriate